epirubicin ( epi-dx ) , a new analog of doxorubicin , was administered i.v . once q 3 weeks at the dose of 90 mg/m2 to 20 evaluable patients with non-hodgkin 's lymphomas ( nhl ) .
C0014582
epi-dx
C0013089
doxorubicin